Donidalorsen for the prophylactic treatment of hereditary angioedema

Donidalorsen is in clinical development for the preventive treatment of patients with hereditary angioedema (HAE). HAE is a rare inherited disorder characterised by recurrent episodes of the accumulation of fluids outside of the blood vessels, blocking the normal flow of blood or lymphatic fluid and causing rapid swelling of tissues in the hands, feet, limbs, face, intestinal tract, or airway causing discomfort and pain (angioedema). HAE may be life-threatening when the swelling occurs in the throat as it can obstruct the airways and impede breathing. HAE has no known cure, and the goal of treatment is to minimise the burden of illness on patients and enable them to lead normal lives.
Donidalorsen works